Epidermal growth factor fusion toxin
Alternative Names: DAB389-EGF; EGF diphtheria toxin chimeric proteinLatest Information Update: 18 Sep 2006
At a glance
- Originator Seragen
- Developer Eli Lilly and Company; Seragen
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Epidermal growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Coronary artery restenosis; Non-small cell lung cancer; Psoriasis; Solid tumours
Most Recent Events
- 18 Sep 2006 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 13 Jun 2003 Preclinical trials in Solid tumours in USA (unspecified route)
- 07 Feb 2001 Discontinued-II for Non-small cell lung cancer in USA (Unknown route)